Please provide your email address to receive an email when new articles are posted on . Patients had a reduced risk for disease progression or death when treated with daratumumab-lenalidomide vs.

Please provide your email address to receive an email when new articles are posted on . Symptoms were associated with 2-nitropropane and 2,4,6-trichlorophenol across three exposure periods. Other ...

(ORLANDO, Dec. 9, 2025) Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed ...